UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts. The ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...